Overview

GlyGenix Therapeutics, Inc. has utilized a combination of scientific and business expertise to create an entire program designed to treat Glycogen Storage Disease Type 1a, for which there is no cure. Utilizing the most advanced technical applications in the fields of molecular biology and Ultrasound gene delivery, GlyGenix Therapeutics, Inc. is engaged in novel strategies to manufacture and deliver genes to cure GSD1a.

The focus of GlyGenix Therapeutics, Inc.'s technology is the development of a universally adaptable non-viral gene delivery system for the treatment of GSD1a.

GlyGenix Therapeutics, Inc. has developed a G6Pase gene delivery approach to treat GSD1a

Technologies currently being developed include:

• G6Pase expression cassettes
• Microbubble and ultrasound plasmid (USP) delivery in collaboration with Philips Corporation (since we do not have the internal capabilities)

Advantages of G6Pase-USP delivery over all other currently proposed gene therapy modalities:

• Non-viral delivery system
• Targeted delivery
• Reduce off target effects